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Abstract 
Background: Randomized controlled trials (RCTs) are the ‘gold standard’ for 
assessing new interventions. The CONSORT statement designed to improve the 
quality of reporting RCTs. The novel oral anticoagulants (NOACs) appear to be a 
good alternative to traditional anticoagulation with warfarin for prevention of stroke 
and systemic embolism in patients with atrial fibrillation (AF). Despite the rapid 
increase in research in NOACs, little is known about the reporting quality of RCTs 
exploring the efficacy and safety of the NOACs versus warfarin in patients with AF. 
Aim: We utilized the CONSORT 2010 statement to assess the reporting quality of 
published RCTs comparing the efficacy and safety of the NOACs versus warfarin in 
patients with AF. 
Methods: A systematic literature search was performed for publications of RCTs 
comparing NOACs to warfarin in patients with AF. Papers were scored against the 25 
items in the CONSORT 2010 checklist. 
Results: Five articles were identified. The total quality scores on the CONSORT 2010 
checklist ranged between 67.6% and 78.4%, with a mean score of 72.5%. 
Conclusion: The overall reporting quality of published RCTs in this field was 
satisfactory. The adoption of the CONSORT statement seems to improve the quality 
of both the conduct and reporting of trials. 
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Introduction 
The assessment of new drugs and treatments is extremely important to the clinician in 
the selection of best therapy. 
Randomized controlled trials (RCTs), as the ‘gold standard’ of evidence based clinical 
practice, are generally considered to have the highest level of credibility in 
determining the efficacy of a new treatment. 
Well-designed and properly conducted randomized controlled trials (RCTs) provide 
the most reliable evidence in health interventions. This, in turn, leads to improvement 
in the prevention or treatment of disease (1). 
Many RCTs have been conducted with adequate methodological rigor to advance 
scientific knowledge. The ability to evaluate and disseminate this knowledge directly 
rests on the transparent and thorough reporting of trial methodology and findings.  
In most cases the RCT report is the only source for clinicians, guideline developers, 
and other researchers to judge the validity and generalisability of the results, so the 
quality of reporting of trials is of inherent interest. 
The lack of adequate reporting influences readers’ interpretation of the evidence and 
makes it more difficult to replicate the results for future research and follow 
recommended treatment options (2, 3). 
To alleviate this problem, guidelines have been created to assist researchers, peer 
reviewers, and journal editors in complete reporting of RCTs. 
The Consolidated Standards of Reporting Trials (CONSORT) statement 
(http://www.consort-statement.org) is a minimum set of evidence-based 
recommendations designed to improve the quality of reporting RCTs. It was initially 
published in 1996 (4), then revised twice subsequently in 2001 and 2010 (5, 6). 
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The revisions were each accompanied by a detailed explanation and elaboration 
document for the purpose of enhancing the use, understanding, and dissemination of 
the statement (7, 8).  
The CONSORT provides structured guidance to help researchers prepare reports of 
trial findings, facilitate complete and transparent reporting, and aid in critical 
appraisal and interpretation. The most current version of the statement includes a 25-
item checklist (Picture 1, 2) and a flow diagram (Figure 2). The checklist provides 
standardized approaches to report the trial design, analysis, and interpretation, and the 
diagram gives instructions to display the progress of all participants throughout the 
trial. 
Some journals require that manuscripts reporting the results of RCTs include the 
CONSORT flow diagram (Figure 2) showing the progress of patients throughout the 
trial, and that the CONSORT checklist (Picture 1, 2) also be completed and submitted 
with the manuscript. The Journal of the American Medical Association (JAMA), the 
Lancet and Annals of Internal Medicine all endorse the CONSORT statement. Even in 
those journals that require CONSORT compliance reporting on submitted trials, the 
published RCTs are not always 100% CONSORT-compliant. 
 
 
Since the initial publication, the quality of clinical trial reporting has improved over 
the years in general (9, 10) and in many medical specialties (11-13). However, the 
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quality of reporting is far from satisfactory, and incompleteness and inaccurate 
reporting of trial results compounded with poor methodological rigor remain a serious 
concern (the authors may have used the correct methodology, but may not have 
explicitly reported all of the methodology used) (10, 14-16). 
A number of publications have studied the quality of reports of RCTs in subspecialties 
of medicine (17-22). 
Cardiology is a specialty in which a large volume of research is conducted annually. 
Systematic evaluation on the reporting quality of RCTs exploring the efficacy and 
safety of the new anticoagulants versus warfarin in patients with atrial fibrillation, 
based on the adherence to the CONSORT statement, has never been reported before. 
Atrial fibrillation (AF) is a common cardiac arrhythmia associated with increased 
morbidity and mortality. Patients with AF sustain an increased risk of arterial 
thromboembolism and stroke. Therefore, antithrombotic strategies using anticoagulant 
drugs and antiplatelet agents are recommended for patients with AF presenting with 
risk factors for stroke. Antithrombotic therapy is also associated with a risk of 
bleeding; therefore, the beneficial effects on stroke prevention should always be 
compared against a patient’s risk of major bleeding. 
Existing guidelines recommend anticoagulant therapy for patients at intermediate or 
high risk of stroke (23). Although standard adjusted dose vitamin K antagonist (VKA) 
(eg. warfarin) (24, 25) has been the cornerstone treatment (until 2009, warfarin and 
other vitamin K antagonists were the only class of oral anticoagulants available) for 
reducing the risk of stroke or systemic embolism (SE) in this population, it is 
associated with several drawbacks (narrow therapeutic range, drug and food 
interactions, regular monitoring, and risk of bleeding) which have prompted the 
development of novel (newer) oral anticoagulants (NOACs) such as direct thrombin 
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[Dabigatran (Pradaxa)] and factor Xa [eg. Apixaban (Eliquis), Edoxaban (Lixiana, 
Savaysa), Rivaroxaban (Xarelto)] inhibitors (Figure 1). Dabigatran etexilate is a 
prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran. 
The novel oral anticoagulants (NOACs) appear to be a good alternative to traditional 
anticoagulation with vitamin K antagonists (VKAs). They have better oral 
bioavailability with less food and drug interactions. They do not require frequent INR 
monitoring and seem to be well tolerated in the long-term use. 
Individually, the NOACs are at least as safe and effective as warfarin for prevention 
of stroke and systemic embolism in patients with AF (26-30). 
The aim of this study was to assess the reporting quality of randomized controlled 
trials (RCTs) exploring the efficacy and safety of the new anticoagulants versus 
warfarin in patients with atrial fibrillation, based on CONSORT statement.  
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Figure 2. Flow diagram of the progress through the phases of a parallel randomised 
trial of two groups (enrolment, intervention allocation, follow-up, and data analysis) 
(http://www.consort-statement.org) 
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Picture 1. CONSORT 2010 checklist 
 
 
Picture 2. CONSORT 2010 checklist (continued) 
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Methods 
 
Study Selection 
We systematically searched the publications of RCTs comparing new oral 
anticoagulants (NOACs) to warfarin in patients with AF. 
A systematic literature search of MEDLINE (PubMed) and Cochrane databases from 
inception to July 2015 was performed. 
The following were used as medical subject heading terms and/or keywords: “atrial 
fibrillation”, “warfarin”, “dabigatran”, “rivaroxaban”, “apixaban”, “edoxaban”. 
Reference lists of all studies included in the present systematic review, were screened 
for potential additional eligible studies. 
Studies were included if they met the following selection criteria: (1) they were phase 
III randomized controlled trials (RCTs) between NOACs and warfarin, (2) all the 
patients were randomized to warfarin (comparator) or to non-vitamin K antagonist 
oral anticoagulants (NOACs) (in our present study, we defined apixaban, dabigatran, 
edoxaban and rivaroxaban as NOACs), (3) the population of interest was patients with 
atrial fibrillation (AF), irrespective of cause (adults aged 18 years and older with 
nonvalvular AF-no criteria were enforced for gender), (4) to assess the long-term 
efficacy and safety of these agents, only RCTs with follow-up duration at least 1 year 
were included, (5) they were published in English language, (6) studies performed in 
humans. Except blinded, the open-label studies were also included because of the 
need of frequent INR monitoring for warfarin. For all the included studies, the 
primary efficacy endpoint was composite of stroke and systemic embolism. The 
secondary efficacy endpoints included ischemic stroke, hemorrhagic stroke, all-cause 
mortality, and myocardial infraction. For safety evaluation, the main endpoint was 
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major bleeding defined as fatal bleeding or bleeding in a critical site, and the 
secondary endpoint included gastrointestinal and intracranial bleeding. We only 
considered the studies approved or in development, so the studies for ximelagatran, 
which had been withdrawn (because of hepatoxicity) (31) and studies for darexaban, 
which is no longer in development (32) were excluded from our analysis. 
Conference abstracts and presentations were also excluded, because their results may 
not be final and such publications undergo more limited peer review. 
 
Data Extraction and Reporting Assessment Tool 
As assessment tool for quality of reporting of randomized controlled trials (RCTs), we 
used the CONSORT checklist, revised in 2010, which includes a 25-item 
questionnaire (http://www.consort-statement.org). Papers were scored against the 25 
items in the 2010 CONSORT statement (each item was given an equal weighting). 
Each item was subdivided as outlined in the CONSORT statement: 12 items were 
divided into a and b parts giving a total of 37 points scored per paper. Hence, based on 
CONSORT reporting items, we developed a 37-items data extraction sheet (Table 2). 
We reviewed each article and determined whether the RCT paper reported on each of 
the 37 items of the revised CONSORT statement. 
All items were investigated in terms of whether they were reported, not whether they 
were actually carried out during the trial. Each item was characterised as ‘yes’ if it 
was clearly and adequately reported in the trial or ‘no’ if it was partially reported, 
unclear, or not reported at all. 
Each ‘yes’ answer received a score of 1 and each ‘no’ answer was scored as 0.  
We conducted a descriptive statistical analysis of all evaluated articles. Data were 
analyzed using Microsoft Excel 2007 and SPSS software (version 19.0). 
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In order to assess adherence to CONSORT checklist items, we calculated the number 
and proportion of trial articles that clearly and adequately reported each of the 37 
CONSORT items (proportion of each item = the number of articles that reported the 
item /total articles-for example, if 3 of 5 RCTs reported item 8a on the checklist, that 
item would score an overall compliance score of  60%) (Table 2) (Figure 4). 
Although all items in the CONSORT checklist are considered important as to improve 
the quality of reports of RCTs, emphasis was placed on reporting of methodological 
items which are more specific to assess the methodological quality of RCTs, that is 
sample size, randomization (sequence generation, allocation concealment, 
implementation), blinding, performed statistical methods, description of baseline data, 
precision of estimated effect size and reporting of ITT analysis. 
Explaining more specifically some methodological CONSORT criteria: i) 
randomization is the method used to generate the random allocation sequence, 
including details of any restriction (e.g. blocking, stratification) ii) allocation 
concealment is the method used to implement the random allocation sequence (e.g. 
numbered containers or central telephone), clarifying whether the sequence was 
concealed until interventions were assigned and iii) implementation of randomization 
answers the question of who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their groups. 
The number and percentage of articles reporting each applicable section on the  
CONSORT checklist was also calculated (proportion of each section =the sum of 
items percentage of each section/total items of each section) (Table 4). 
The total quality of reporting score (the CONSORT score) of each trial article was 
calculated as a proportion of the ‘yes’ rated applicable items on the CONSORT 
checklist (possible range 0-37 points) (CONSORT score of each article = the number 
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of reported items/37 items-for example, a RCT reporting 20 of the 37 items on the 
checklist would score 54.1%) (Table 3), which was used to inform a global 
assessment of the quality of reporting. 
 
Results 
Our literature search identified a total of 917 articles.  
After removing duplicates, we screened titles and abstracts and the full text of 68 
publications was retrieved and evaluated for eligibility. Five trials (RE-LY, 
ARISTOTLE, ENGAGE AF-TIMI 48, ROCKET AF, J-ROCKET AF)  that met our 
inclusion criteria were identified and included in the present study (Figure 3). 
 
 
Figure 3.  Flow chart of study selection process  
Records identified through 
database searching 
(n=917) 
Records after 
duplicates removed 
(n=679) 
Records screened 
based on title and 
abstract  
(n=679) 
Records excluded 
 Not in English 
 Not related to topic 
 Not RCTs phase III 
 Follow-up < 1 year 
 Other studies/reviews 
Records assessed 
for eligibility 
based on full text 
(n=68) 
5 studies included in 
final assessment 
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The number of trials examining each drug were: one for apixaban (ARISTOTLE) 
(28), one for edoxaban (ENGAGE AF-TIMI 48) (29), one for dabigatran (RE-LY) 
(26) and two for rivaroxaban (ROCKET AF, J-ROCKET AF) (27, 30). 
The 5 included randomized clinical trials assessed the relative efficacy and safety of a 
new oral anticoagulant, apixaban, dabigatran, rivaroxaban or edoxaban, compared to 
warfarin in patients with atrial fibrillation (AF). 
They were each designed to determine if the study drug was noninferior to warfarin 
with respect to the composite end point of all stroke and systemic embolism. 
These randomized clinical trials have a number of similar conclusions. 
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a 
randomized trial designed to compare two fixed doses of dabigatran, each 
administered in a blinded manner, with open-label use of warfarin [target international 
normalized ratio (INR), 2.0 to 3.0] in patients who had AF and were at increased risk 
for stroke (26). In this noninferiority trial, 18,113 patients were randomized. The 
median duration of the follow-up period was 2.0 years. 
In conclusion, in patients with atrial fibrillation, dabigatran given at a dose of 110 mg 
twice daily was associated with rates of stroke and systemic embolism that were 
similar to those associated with warfarin, as well as lower rates of major hemorrhage. 
Dabigatran administered at a dose of 150 mg twice daily, as compared with warfarin, 
was associated with lower rates of stroke and systemic embolism but similar rates of 
major hemorrhage. 
In ARISTOTLE, 18,201 patients with nonvalvular AF were randomized to either 
apixaban 5 mg twice daily or to warfarin (28). 
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In conclusion, in patients with atrial fibrillation, apixaban was superior to warfarin in 
preventing stroke or systemic embolism, caused less bleeding, and resulted in lower 
mortality. 
 ROCKET AF compared a 20 mg/day dose of rivaroxaban to warfarin in 14,264 
patients with nonvalvular AF (27). 
In conclusion, in patients with atrial fibrillation, rivaroxaban was noninferior to 
warfarin for the prevention of stroke or systemic embolism. There was no significant 
between-group difference in the risk of major bleeding. 
The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–
Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) was a 
randomized trial designed to compare two once-daily regimens of edoxaban with 
warfarin in 21,105 patients with moderate-to-high-risk AF (29). 
In conclusion, both once-daily regimens of edoxaban were noninferior to warfarin for 
the prevention of stroke or systemic embolism. 
J-ROCKET AF trial, compared the safety of a Japan-specific rivaroxaban dose with 
warfarin administered according to Japanese guidelines in Japanese patients with AF 
(30). 
The main characteristics of the included trials are summarized in Table 1. 
Reporting quality assessment of included trials was conducted using the CONSORT 
statement. 
Table 2 shows the adherence of the selected RCTs to the CONSORT statement. 
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Table 1. Main characteristics of included randomized clinical trials 
Trial NOAC Intervention Patients Follow-up period 
(median) 
Trial 
design-
double 
blind 
CHADS2* 
score 
(mean) 
RE-LY (26) Dabigatran Warfarin/ Dabigatran 150 mg 
Dabigatran 110 mg 
18,113 2.0 years No 2.1 
ROCKET AF (27) Rivaroxaban Warfarin/ Rivaroxaban 20 mg 14,264 1.9 years Yes 3.48 
ARISTOTLE (28) Apixaban Warfarin/ Apixaban 5 mg 18,201 1.8 years Yes 2.1 
ENGAGE AF-TIMI 48 (29) Edoxaban Warfarin/Edoxaban 60 mg 
Edoxaban 30 mg 
21,105 2.8 years Yes 2.8 
J-ROCKET AF (30) Rivaroxaban Warfarin/ Rivaroxaban 15 mg 1,280 1.3 years (mean) Yes 3.27 
 
* The CHADS2 score, an index of the risk of stroke in patients with atrial fibrillation, ranges from 1 to 6, with higher scores indicating a greater  
risk of stroke 
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Table 2. Reporting quality of 5 RCTs based on CONSORT 2010 
Section/Topic Item Number Item description Adherence 
[n (%)] 
Title and abstract 1a Identification as a randomised trial in the title 0  
1b Structured summary of trial design, methods, results, and 
conclusions 
5 (100) 
Introduction Background 
and objectives 
2a Scientific background and explanation of rationale 5 (100) 
2b Specific objectives or hypotheses 5 (100) 
Methods Trial design 3a Description of trial design (such as parallel, factorial) 
including allocation ratio 
5 (100) 
3b Important changes to methods after trial commencement 
(such as eligibility criteria), with reasons 
2 (40) 
Participants 4a Eligibility criteria for participants 5 (100) 
4b Settings and locations where the data were collected 2 (40) 
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Interventions 5 The interventions for each group with sufficient details to 
allow replication, including how and when they were 
actually administered 
5 (100) 
Outcomes 6a Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were 
assessed 
5 (100) 
6b Any changes to trial outcomes after the trial commenced, 
with reasons 
0 
Sample size 7a How sample size was determined 4 (80) 
7b When applicable, explanation of any interim analyses and 
stopping guidelines 
2 (40) 
Randomisation: 
Sequence 
8a Method used to generate the random allocation sequence 3 (60) 
8b Type of randomisation; details of any restriction (such as 2 (40) 
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generation blocking and block size) 
Randomisation: 
Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until 
interventions were assigned 
0 
Randomisation: 
Implementation 
10 Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants to 
interventions 
0 
Blinding 11a If done, who was blinded after assignment to 
interventions (for example, participants, care providers, 
those assessing outcomes) and how 
5 (100) 
11b If relevant, description of the similarity of interventions 4 (80) 
Statistical 
methods 
12a Statistical methods used to compare groups for primary 
and secondary outcomes 
5 (100) 
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12b Methods for additional analyses, such as subgroup 
analyses and adjusted analyses 
4 (80) 
Results Participant 
flow (a diagram 
is strongly 
recommended) 
13a For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
4 (80) 
13b For each group, losses and exclusions after 
randomisation, together with reasons 
5 (100) 
Recruitment 14a Dates defining the periods of recruitment and follow-up 5 (100) 
14b Why the trial ended or was stopped 0 
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group 
5 (100) 
Numbers 
analysed 
16 For each group, number of participants (denominator) 
included in each analysis and whether the analysis was by 
original assigned groups 
5 (100) 
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Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each 
group, and the estimated effect size and its precision 
(such as 95% confidence interval) 
5 (100) 
17b For binary outcomes, presentation of both absolute and 
relative effect sizes is recommended 
0 
Ancillary 
analyses 
18 Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
5 (100) 
Harms 19 All important harms or unintended effects in each group 5 (100) 
Discussion Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
4 (80) 
Generalisability 21 Generalisability (external validity, applicability) of the 
trial findings 
5 (100) 
Interpretation 22 Interpretation consistent with results, balancing benefits 5 (100) 
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and harms, and considering other relevant evidence 
Other 
information 
Registration 23 Registration number and name of trial registry 5 (100) 
Protocol 24 Where the full trial protocol can be accessed, if available 3 (60) 
Funding 25 Sources of funding and other support (such as supply of 
drugs), role of funders 
5 (100) 
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Percentage of articles that fulfill the individual criteria of the CONSORT 
checklist
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Figure 4. Percentage of articles that fulfill the individual criteria of the CONSORT 
checklist
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The articles report on most of the items on the CONSORT 2010 statement, but none 
of the articles reported all 37 items (no paper scored fully on all items of the 
CONSORT 2010 guidelines). The total scores on the CONSORT 2010 checklist 
ranged from 25 to 29, with a mean score 26.8±1.79 of 37 items (the total scores on the 
CONSORT 2010 checklist ranged between 67.6% and 78.4%, with a mean score of 
72.5% and standard deviation of 4.83%) (Table 3). 
Consequently, the average adherence of the selected RCTs articles to the CONSORT 
statement was 72.5%.   
Some methodological items from the checklist, including  “randomization” (sequence 
generation), were poorly described, while we assessed most other items as adequately 
reported. Of all methodological items of the CONSORT statement, allocation 
concealment mechanism and randomization implementation were omitted in the 
selected studies. 
Specifically, the following findings are summarized in Table 2: 
None of all trial reports stated in the title of the report that the trial was randomized. 
For the item relating to abstract content there was a high level of compliance (100%). 
All RCTs reports introduced a scientific background and an explanation of rationale. 
All articles reported hypothesis and objectives 
Description of the trial design was reported by all the included studies. 
Two trial reports mentioned important changes to methods after trial commencement. 
All studies (100%) reported adequate information regarding the eligibility criteria for 
study participants. 
Forty percent (2/5) of all trial reports provided the locations of the trial data 
collection. 
There was 100% reporting of the details of the intended intervention in each group. 
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All trial reports (5/5) defined the primary and secondary outcome measures. 
None of the trials reported any changes to trial outcomes after the trial commenced. 
80% of trial papers (4/5) stated that an estimation of sample size had been done. 
Two studies reported that interim analyses had been applied. 
The method used to generate the random allocation sequence in the RCTs was 
reported from three papers (60%): Randomization was performed with the use of a 
central, 24-hour, computerized, automated voice-response system (ROCKET AF); 
Randomization was performed with the use of a central, 24-hour, interactive, 
computerized response system (ENGAGE-TIMI 48); all trial participants were 
randomly assigned to receive one of two doses of dabigatran, or to receive warfarin, 
by means of a central, interactive, automated telephone system (RE-LY). 
Only two studies (40%) reported the type of randomization. 
While all of these studies were reported as RCTs, none of the articles described the 
allocation concealment mechanism and the personnel who implemented the 
randomization process, i.e. none of the trial reports provided information on who 
generated the random allocation sequence, administered the intervention and/or 
assigned the intervention groups. 
All articles reported whether there was any blinding. 
In addition to reporting who was blinded, 80% (4/5) of the trial reports provided 
information on how blinding was achieved. 
All RCTs articles reported statistical methods.  
Four studies (80%) reported the methods for additional analyses (such as subgroup 
analyses and adjusted analyses). 
A participant flow diagram through each stage of the study was given in 80% (4/5) of 
the trial reports. 
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All trial reports provided information on any loss and exclusion after randomization, 
for each study group. 
All trial reports (5/5) supported information on the time of the recruitment period and 
the follow-up period.  
All trial reports used a table to show baseline demographic and clinical characteristics 
for each group. 
All trial reports (100%) stated any information about "intention-to-treat" analysis. 
All trial reports (100%) stated the estimates of the precision of estimated effect size 
(i.e. presentation of 95% confidence intervals). 
All trial articles included reporting of the use of ancillary analyses. 
All trial reports mentioned adverse or unintended effects in each group.  
Four trial reports analyzed the trial limitations and all balanced the benefits and harms 
of the results. 
Generalizability of the trial findings, was reported by 100% of the included trials. 
Registration numbers or names of trial registries were reported by all studies. 
(The first U.S. federal law requiring trial registration was established in 1997 and the 
registry of ClinicalTrials.gov was released by the National Institutes of Health in 
2000). 
Of all articles reviewed, 60% (3/5) reported where the full trial protocol could be 
accessed. 
The details of the funding sources were provided in all trial reports (all the trials were 
fully funded by industry). 
Table 3 presents an overall quality score for each trial as a global assessment of the 
quality of reporting. 
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Table 3. The total scores on the CONSORT 2010 checklist by year of publication and 
study name 
Study name Journal name Publication year CONSORT 2010 
statement score* $ 
RE-LY The New England 
Journal of 
Medicine 
(NEJM.org) 
2009 25 (67.6%) 
ROCKET AF The New England 
Journal of 
Medicine 
2011 27 (73.0%) 
ARISTOTLE The New England 
Journal of 
Medicine 
2011 28 (75.7%) 
J-ROCKET AF Circulation Journal 2012 25 (67.6%) 
ENGAGE AF-
TIMI 48 
The New England 
Journal of 
Medicine 
2013 29 (78.4%) 
 
* The score for each article was calculated as the total points scored for this article 
divided by the number of applicable items. For example, the RE-LY trial article, that 
fulfilled 25 items from the CONSORT 2010 checklist out of applicable 37 items, 
received a score of 67.6%. 
$ The higher the percentage, the more adequately authors reported their trial. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:34 EET - 137.108.70.7
 29 
These articles were published in the post-CONSORT period, after 1996 and were 
retrieved from the journals: 
The New England Journal of Medicine (impact factor: 55.873) and the Circulation 
Journal (impact factor: 14.430) which require the CONSORT checklist and flow 
diagram to accompany any reports of RCTs-have endorsed the CONSORT statement. 
Table 4 summarizes the average reporting percentage for each section of the 
CONSORT checklist of the included trials. The reporting percentage for the ‘title and 
abstract’ section was 50%, for the ‘introduction’ section 100%, for the ‘methods’ 
section 62%, for the ‘results’ section 78%, for the ‘discussion’ section 94% and for 
the ‘other information’ section 86%. 
 
Table 4. The average reporting percentage for each section of the CONSORT 
checklist of the included trials 
Section Number (n)* Percentage (%)* $ 
Title and abstract 2.5 50 
Introduction 5.0 100 
Methods 3.1 62 
Results 3.9 78 
Discussion 4.7 94 
Other information 4.3 86 
 
* The number and percentage of articles reporting each applicable section on the  
CONSORT checklist 
$ percentage of each section = the sum of items percentage of each section/total items 
of each section 
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Conclusions 
The researchers have the most thorough understanding of the trial, so it is important 
for them to give a complete description of the trial process and a deep analysis of 
outcomes. 
A well-designed and well-reported RCT should meet all of the criteria of the 
CONSORT statement. With adequate reporting, readers will understand what was 
actually done, rather than assume what was done.  
The CONSORT items do not actually assess the quality of the methodology of an 
RCT, but rather assess the reporting of key items that are crucial in determining the 
validity and quality of the RCT. The CONSORT checklist was developed as a 
guideline, not as an actual scale for assessing methodology of an RCT. 
In the present study, we assessed the quality of reporting of randomized controlled 
trials that compared the efficacy and safety of the new anticoagulants versus warfarin 
in patients with atrial fibrillation. The results showed that the overall reporting quality 
of published RCTs was moderate to high. 
These articles reported satisfactorily on many important items (i.e. outcome measures, 
participant criteria, participant flow, sample size calculation, intention-to-treat 
analysis and precision of measurement), making it easy for any reader to determine 
the quality and validity of results without needing to make various assumptions. 
Compliance was poorest for items relating to randomization: although the studies had 
a high score failed to report on the implementation of randomization and  allocation 
concealment mechanism. 
Good randomization protocols aim to produce treatment groups that are comparable 
and have an equal distribution of both known and unknown confounders. Achieving 
patient randomization suitable for a clinical trial is a complex issue. The fact that all 
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items relating to the reporting of randomization (items 8a, 8b, 9, and 10) were poorly 
adhered to, highlights the need for further education regarding this aspect of trial 
description. 
There is no evidence that the failure to mention methodological details equates to the 
lack of methodological knowledge or skills: a method of a trial that is not reported 
does not mean actually that it has not been performed. The reporting of 
methodological aspects of RCTs does not necessarily reflect the conduct of the trial. 
The responsibility for reporting lies not only with the authors. 
Peer reviewers and editors are at fault for not insisting on complete description of the 
studies as dictated by the CONSORT statement.  
The findings of the present study suggest that many investigators engaging in RCTs in 
Cardiology are familiar with the CONSORT statement and understand of how to 
properly design and execute an RCT. 
The study showed that journals such as the New England Journal of Medicine and the 
Circulation Journal, that have adopted the CONSORT checklist, have improved levels 
of compliance in their trial reports. There is good evidence in the literature that the 
adoption of CONSORT statement improves the quality of both the conduct and 
reporting of trials in journals that have taken the decision to make it a requirement for 
submission acceptance. 
Although all papers scored highly, a maximum score of 29 (78.4%) was achieved, no 
papers successfully met all criteria laid out in the 2010 CONSORT statement. This 
suggests that there is still room for improvement when publishing trials in cardiology. 
Trial groups, authors, journals, and funding bodies should work collaboratively to 
improve the quality of trial reporting. 
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Journal editors, reviewers and authors should be encouraged to adhere to the 
CONSORT statement when reporting on RCTs and/or reviewing the reports of RCTs, 
in order to ensure high-quality trials. 
Researchers also need to design research with full understanding of the CONSORT 
reporting guidelines and full consideration of items whose reporting quality is low. 
In conclusion, the reporting of randomized controlled trials that compared the efficacy 
and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation 
in the last decade has been more than adequate, and better in general than in many 
other fields. It seems that funding agencies, investigators, and journals have 
developed a cohesive strategy to implement the reporting standards laid down in the 
2010 CONSORT statement. 
During a period of rapid transition in the healthcare delivery system and especially 
during a period of new pharmaceutical and genetic discoveries, higher quality reports 
are likely to improve RCT interpretation, minimize biased conclusions, and ultimately 
facilitate decision-making about treatment effectiveness. 
The knowledge gained from this study should be viewed as an opportunity for 
improved adherence and increased awareness of the CONSORT statement. 
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